Awakening the Dormant Dragon: Neurological Form of Equine Herpesvirus-1

Disease is very old and nothing about it has changed. It is we who change as we learn to recognize what was formerly imperceptible (John Martin Charcot, 1825-1893).

Recently, a number of racetracks, private veterinary clinics and university teaching hospitals outside of California were shut down to limit the spread of the neurological form of equine herpesvirus-1 (EHV-1) infection. California had at least four reported cases of EHV-1 in 2006 and another four cases so far in 2007, but no facilities have been shut down. In preceding years—with the exception of 2003, when there was a large outbreak at a riding school in Ohio—few and sporadic cases were seen in the United States until 2005, when seven cases in the eastern part of the country were reported.

Why has there been such a sudden increase in the number of EHV-1 cases? Many questions including this one remain unanswered. More research is needed and is currently being conducted to understand the factors involved in the emergence of the neurological form of EHV-1. This Horse Report presents the information we have to date.

Equine herpesvirus-1 is one of a large group of viruses that causes potentially serious disease in horses. EHV-1 has two forms. One causes abortion in mares, while the other causes respiratory infection and neurological problems or myeloencephalopathy—damage to the brain and/or spinal cord. This latter form is of particular concern because it results in a high death rate, it is resistant to prevention by vaccination, and it affects horses of all breeds, ages and vaccination status. It has the potential to cause

— Continued on page 3

Pictured above is Royal Brass, who recovered from a recent infection with the neurological form of EHV-1 after being treated at UC Davis. He finished fourth in his first start back since his recovery. Photo courtesy Vassar Photography, 2007.

INSIDE THIS ISSUE...
Director’s Message .................. 2
Isolation and Quarantine
    Procedures ........................... 5
Diagnostic Testing for EHV-1 .... 7
Status of EHV-1 Vaccination ...... 8
Everyday Biosecurity
    Considerations ...................... 9
Biosecurity Measures for
    Different Situations .............. 10
How to Set Up a Disease
    Isolation Unit ........................ 12
About Viruses .......................... 14
Memorial Endowments ............ 15
Coming Events ...................... 16
A Time for Thoughtful Action, Not Panic

The rise in reported outbreaks of the neurological form of equine herpesvirus-1 (EHV-1) has led to much consternation and discussion among people in the horse industry. While the disease is known to have existed for decades, the apparent rise in the ferocity of the virus and its ability to create spontaneous outbreaks of neurological disease throughout the United States and Europe are beginning to shake the confidence of horse owners and veterinarians alike.

In times like these, the key is to not panic. The four horsemen of the apocalypse can be beaten if we can employ thoughtful responses applied through a cooperative action plan. Disease containment and control is best achieved when all parties—horse owners, private and university veterinarians and animal regulatory officials—work closely and efficiently with each other.

In that spirit, this issue of the Horse Report is dedicated to explaining the facts about the neurological form of EHV-1 infection as we currently understand them based on scientific fact, and to providing some guidelines for disease control that can be used by horse owners and exhibitors. This information is the best information regarding EHV-1 as we know it to date.

There is much more the veterinary profession does NOT know about herpes viruses than what it does. Herpes in both humans and animals is among the most complicated of viruses to understand. Researchers at UC Davis and elsewhere are working continuously to increase our understanding of this organism and its disease-producing ability. As such, you will find updates and possibly changes to currently recommended strategies posted on our Web site or included in future publications. Rest assured that all information provided will have undergone careful scrutiny and validation by the best minds available before it is released.

With regard to the specific information provided here, remember that EHV-1 is not a new disease and that the so-called “neurological mutant strain” has been documented to have existed over the last 35 years. Also, any strain of EHV-1 has the potential to cause neurological disease, so the current fixation on a “new” mutant strain as the cause of the current crisis is not totally accurate.

While it would appear that more horses are becoming ill more often and those affected seem to be sicker and more apt to die, this change in pathogenesis cannot be laid at the feet of a single factor. Nor can the spread of EHV-1 be explained as a simple contagion transmitted from one infected horse to others. Many more exposed horses remain unaffected than the number that become sick in recorded outbreaks.

As a best defense against the spread of EHV-1 infection, this issue of the Horse Report also describes biosecurity measures that can be applied within a horse facility and mechanisms for establishing quarantine and isolation facilities should this become necessary. These guidelines can be adapted to a variety of horse operations by individual horse owners and facility managers.

There is no perfect or foolproof system for any of these procedures. Apply them to your situation as best as possible to minimize the risk of disease transmission without unduly disrupting the normal operations of your facility. Some of these recommendations can be applied in a staged basis in response to increasing or decreasing levels of risk over time. The more imminent the threat, the more intense should be the biosecurity procedures applied. You know the drill already: Homeland Security, blue-yellow-orange-screaming red, run for cover.

Finally, you are not alone in the concern for the safety of your animals. The battle is not yours alone to fight. Talk to your neighbors and stable mates. Make a local plan for action within your town or area. Enlist the support of people with expertise in these areas. There are many of us out there who are willing to help in any way we can. Contact your local veterinarian and ask for advice. Contact us here at UC Davis or those in the California Animal Health and Food Safety system or the California Department of Food and Agriculture for information or help. Get online and look for reputable equine health Web sites.

To paraphrase Rudyard Kipling: If you can keep your head when all about you are losing theirs and blaming it on you, If you can trust yourself when all men doubt you…. yours is a healthy horse and everything around it.
One of the typical neurological effects of EHV-1 infection is the “dog-sitting” posture reflective of pronounced weakness particularly in the hindlimbs. It can produce a fulminating disease (one that occurs suddenly and with great intensity) that rapidly leads to death. However, in other individuals—even in the face of outbreaks—the virus appears to be restricted to latency, much like the herpes simplex type 1 virus in humans.

How Horses Become Sick
EHV-1-induced neurological injury occurs when large numbers of the virus damage small blood vessels in the brain and spinal cord, with resultant damage or dysfunction to tissues. This is not unlike what happens when cardiac blood supply is impaired in human heart attack.

EHV-1 is contagious and is spread by direct horse-to-horse contact, by contaminated hands, equipment and tack, and for a short time, through aerosolization of the virus within the environment of the stall and stable. Therefore, to prevent the spread of infection, it is essential to institute isolation and quarantine measures immediately.

It is also possible that stress factors may reactivate the virus and elicit the onset of clinical signs. These stress factors may include stress from transport, strenuous physical exercise, suppressed immune system, and excessive fatigue.

Clinical Signs of EHV-1
The initial clinical signs of EHV-1 infection may be nonspecific and include fever of 102°F or greater. Fever may be the only abnormality observed. Other signs may be combinations of fever and respiratory symptoms of nasal discharge and cough. Some horses may have reddish mucous membranes, puffy and red eyes, and swollen legs.

Horses with the neurological form of EHV-1 can soon become uncoordinated and weak and have difficulty standing. They may also experience difficulty in urinating and defecating. Often the hindlimbs are more severely affected. Some horses may present with weakness in their hindlimbs, while others may exhibit more severe neurological signs. In some cases, horses may also experience difficulty in urinating and defecating.

One of the typical neurological effects of EHV-1 infection is the “dog-sitting” posture reflective of pronounced weakness particularly in the hindlimbs.
Dormant Dragon
— Continued from page 3

affected than the forelimbs. Hence, “dog-sitting” is not uncommon in sick horses (see photo on previous page). Signs of brain dysfunction may occur as well, including extreme lethargy and a coma-like state.

The incubation period for infection is from 2 to 8 days. Once a fever occurs, clinical signs can progress to nervous system involvement over the next 1 to 7 days.

Vaccinations
While several vaccines are available for protection against the respiratory and abortogenic forms of EHV-1, at this time there is no equine vaccine that has a label claim for protection against the neurological strain of the virus. More details about the current status of EHV-1 vaccination are presented in a later section of this Horse Report.

Until such time as a vaccine is developed to protect horses from the neurological form of EHV-1, the best way to prevent the spread of disease is through isolation, quarantine and the practice of biosecurity—a series of management steps taken to prevent the introduction of infectious agents into a herd. All of these preventive measures are discussed in the following sections. ♦

Clinical signs of neurological EHV-1 infection may include combinations of fever and respiratory symptoms of mild nasal discharge plus or minus a cough.

Other signs include redness of the sclera or conjunctiva, incoordination, weakness and difficulty in standing, and urine dribbling as well as difficulty in urinating and defecating.
Isolation and Quarantine Procedures To Prevent the Spread of EHV-1

Isolation of Sick Horses
Horses exhibiting sudden and severe neurological signs consistent with a diagnosis of EHV-1 pose a threat to the surrounding population of horses. Consequently, early intervention to prevent the spread of infection is critical.

If your horse develops fever, respiratory signs (including nasal discharge or cough) and neurological signs (incoordination, weakness, difficulty standing, lethargy, difficulty controlling urination or defecation), immediately notify your veterinarian and do not move other horses in the immediate area. Alert anyone with a horse in the adjacent area to stop all movement of horses in and out of the facility until a diagnosis is confirmed by PCR testing. If horses are exposed and then travel to a new stable or show, the infection may spread to other horses at that new location.

To prevent an infected horse from having further contact with other horses in the stable environment, an individual horse exhibiting any of the clinical signs described above should be removed immediately from the area of other horses and placed in a separate enclosure designated for infectious disease isolation. Anyone handling infected horses should not be in contact with other horses until thoroughly washing their hands and changing clothes. The isolation stall or enclosure should be located well away from high-traffic areas associated with other barns or training areas.

Animal caregivers should take precautionary measures to ensure that they do not transmit disease to other horses through contaminated hands, clothing, equipment or tack. It is essential that the isolation facility have supervised oversight by an individual trained in disease control and quarantine procedures to avoid the possibility of contamination.

EHV-1 in infective amounts does not persist in the environment for a long time, but disinfection of premises, stalls, trailers and other equipment or facilities is important. If you handle a horse with EHV-1 and don’t wash hands or change clothing, you may spread the infection to other horses. A solution of 1 part chlorine bleach to 10 parts water is effective for decontaminating equipment and environment. Other commercial preparations for disinfection are available through your veterinarian.

Segregation of Exposed Horses
Horses known to have had intimate contact with the diagnosed clinical case of EHV-1 should be maintained in their existing barns and segregated from other horses during exercise periods until the sick horse has been confirmed to have EHV-1 by PCR testing (see page 7).

Quarantine Procedures
Once EHV-1 infection has been confirmed, appropriate focal quarantine measures to restrict the movement of all potentially exposed horses will be necessary to prevent the spread of disease to other locations.

These procedures may begin with initial restrictions such as the quarantine of horses in the immediate area of exposure (i.e., a single barn or other unit of housing) within a horse facility. Horses in the immediate contact area of the clinically affected horse(s) should have their temperatures taken twice daily and if a fever develops be tested for EHV-1, as should any other horse that exhibits fever or other clinical signs consistent with EHV-1 infection. Since stress may play a role in eliciting the onset of clinical signs, horses stabled in areas of known exposure should not be subjected to strenuous physical exercise or long-distance transport until their health status can be determined.

Expanding the Quarantine Area
If new clinically ill or EHV-1 positive horses are identified in other locations within the equine facility, an additional focal quarantine of exposed horses should be instituted at that location. The area under quarantine may be expanded to include other affected barns.

— Continued on page 6
Isolation/Quarantine
— Continued from page 5

If multiple cases are identified or suspected, the entire stable area may need to be quarantined. The optimum strategy should be prudent imposition of a series of focal quarantine procedures using an expanding series of “concentric rings” (larger and larger rings, as needed) of disease control.

Individual animals that have tested positive for EHV-1 within the designated quarantine area, whether symptomatic or not, should be retested periodically until disease is confirmed or eliminated based on both a negative PCR test and a lack of clinical signs for the disease.

Quarantine measures should be maintained until an absence of further clinical cases and positive tests suggest no new appearance of disease is occurring. At that time, a gradual drawdown of these quarantine procedures can be started. Areas of the facility under focal quarantine may have their restrictions rescinded in a reverse of the concentric-ring approach. The general guideline is to wait for 21 days after the last fever related to EHV-1, or if testing is negative in all exposed horses, quarantines have been lifted sooner.

Horses Outside the Quarantine Areas

Since the positive predictive value of PCR-based tests for EHV-1 in horses with no clinical signs is uncertain at this time, horses outside of quarantine areas or in unexposed stables should not be tested on a random basis. The finding of a positive PCR test result in an asymptomatic horse does not provide conclusive evidence of either active infection or the potential for disease transmission. Because of the known tendency of EHV-1 for latency, low levels of nonreplicating virus (not capable of spreading infection) may be the source of the viral DNA detected in any asymptomatic individual.
Infectious diseases such as equine herpesvirus-1 are diagnosed using molecular techniques rather than conventional laboratory techniques of antigen detection, microscopy and culture because the results can be obtained much more rapidly and with a greater degree of accuracy. Polymerase chain reaction (PCR) is the best molecular technology currently in use.

PCR works by detecting and then amplifying the DNA of an infectious agent. In the testing process, a very small amount of DNA or RNA from a virus, for example, can be detected and replicated into a million copies. The amplified specific genetic code sequence for that virus is then compared against a known specific sequence using computer-assisted technology. A test for a specific agent (virus) is made when there is a correlation between the acquired sample and a known viral sequence.

Sometimes some strains of bacteria or viruses may mutate and incorporate a small change in its genetic code for a particular strain of the same virus. This can cause the reaction to miss the sequence it is looking for and elicit an inconclusive result. However, tests are always being improved as new variants are found by scientists. PCR is a useful research and diagnostic tool, but all applications require extreme care and vigilance.

Since EHV-1 is considered to be endemic within the horse population, random testing of normal horses for EHV-1 by PCR can and likely will detect horses with nonreplicating (dead) viral DNA; latent (dormant) low levels of virus; or viral levels that are not sufficient to pose a significant risk for disease transmission.

With the current outbreaks of EHV-1, the interpretation of PCR detection for the virus should be done only in the context of presenting clinical signs for disease. If PCR testing for a horse with clinical signs for EHV-1 indicates a high viral load for EHV-1, we recommend that other tests be undertaken as a follow-up to initial PCR testing to determine whether the virus is replicating (also PCR testing to determine RNA transcription). Additional testing can also be used to determine the viral load (amount of virus present in blood or nasal secretion) in any clinically ill horses. Viral load levels may potentially indicate the stage of disease progression for individual patients.

At this time, the significance of a positive PCR test in a horse with no clinical signs for the disease is unknown. There is currently insufficient information to justify or recommend control measures or quarantine procedures for horses testing positive for EHV-1 in the absence of clinical signs, unless they are known to have had intimate contact with a known clinical case.
Status of Vaccination Against EHV-1 Myeloencephalopathy (Neurological Form)

by W. David Wilson, BVMS, MS

In the wake of recent outbreaks of the neurological form of EHV-1 (known as myeloencephalopathy) in populations of horses in several regions of North America, many racing jurisdictions and managers of equine facilities and events have imposed EHV-1 vaccination requirements for incoming and resident horses in the hope that EHV-1 infection—particularly the neurological form—can be prevented. The efficacy of this approach remains to be proven. In fact, frequent revaccination of mature horses to prevent the neurological form of EHV-1 is not clearly justified in most circumstances for the following reasons:

- Most mature horses have been infected previously with EHV-1 and are latent carriers.
- Neurological EHV-1 is a relatively rare disease from a population standpoint.
- Neurological form of EHV-1 has been observed in horses vaccinated against EHV-1 regularly at 3- to 4-month intervals.
- Currently available vaccines do not reliably block infection or claim to prevent neurological EHV-1.
- Vaccination has been cited by some as a potential risk factor for development of neurological EHV-1.

On the other hand, regular revaccination of pregnant mares and other horses on breeding farms to reduce the risk of EHV-1 induced abortion is strongly recommended.

Commercially available vaccines for EHV-1 include two single-component inactivated vaccines (Pneumabort K and Prodigy) marketed for the prevention of abortion in pregnant mares; several multi-component inactivated vaccines (Prestige, Calvenza, Innovator); and one MLV vaccine (Rhinomune) for the prevention of respiratory disease induced by EHV-1 and EHV-4. Each of these vaccines induce some, but not all, of the desired components of the immune response in the horse. Therefore, it is not surprising that NONE induces sterile immunity or complete protection from clinical disease. The best that can be hoped for is a reduction in the severity of clinical signs and in the amount of EHV-1 shed by vaccinated horses that do become infected.

There is evidence that viral shedding is reduced in horses with high circulating titers of virus-neutralizing (VN) antibody, as well as in those that have been vaccinated recently with the Rhinomune MLV vaccine. Of the available inactivated vaccines, Calvenza and both vaccines marketed for prevention of abortion (Pneumabort K and Prodigy) contain the highest amounts of antigen and stimulate the highest levels of VN antibody in experimental horses.

On premises with confirmed clinical EHV-1 infection (any form), booster vaccination of horses that are likely to have been exposed already is not recommended. However, it seems rational to booster vaccinate nonexposed horses as well as horses that must enter the premises with one of the four vaccines listed above if they have not been vaccinated against EHV-1 within the past 90 days. This approach relies on the assumption that the immune system of most mature horses has already been “primed” by prior exposure to EHV-1 antigens through field infection or vaccination and can therefore be “boosted” within 7 to 10 days of administration of a single dose of vaccine.

While this approach does not guarantee protection of individual horses against the potentially fatal neurological form of EHV-1, the hope is that reduced nasal shedding of infectious EHV-1 by recently vaccinated horses will indirectly help protect other horses by reducing the dose of virus to which they are exposed.

Ultimately, enforcement of strict biosecurity measures and hygiene practices are likely to be more effective than widespread vaccination in reducing the risk of acquiring EHV-1 infection.
Recent outbreaks of equine herpesvirus-1 have brought awareness of the need to handle our horses in a manner that prevents transmission of infection. The term for this is biosecurity, which means taking measures that prevent transmission of an infection to your horse.

Two ways that horses and humans may catch many infectious diseases are by direct contact and/or by aerosol spread via the air.

Direct contact means physical contact with a horse that has an ongoing active infection or is in the early incubation period of infection and ready to break with a fever. It is possible, however, to catch a virus or bacteria from a horse without that horse having a fever or other signs of infection. Direct-contact transmission can also occur when a person touches a horse and has the agent on their hands, tack, bridle, saddle pad, bucket or shoe and then spreads the infectious agent via use of that contaminated equipment on another horse. Herpes viruses are largely spread by direct contact.

Aerosol spread means that the infectious agent travels through the air and causes infections by breathing the agent in. Most respiratory viruses of the influenza group spread this way. Indeed these viruses can travel significant distances, depending on air flow, temperature and other environmental conditions. Strangles horses may cough and spread that bacteria throughout a barn or stable.

However, it has become clear in recent weeks that aerosol spread has not been a primary means of transmission of EHV-1.

Biosecurity Measures

• Have a policy for your stable for horses that leave and attend horse events. Horses returning from distant events should have minimal contact with other horses. Upon returning to the stable, travel horses should ideally be isolated from the home stable population for at least 2 weeks.

• While traveling, if it is known that at the event there were sick horses, take your horse’s temperature twice daily and report a fever (101.5°F or greater) to the stable manager and your veterinarian.

• Avoid petting and touching other horses to minimize the chance of infecting your horse.

• Use separate water buckets, feed troughs, tack and grooming equipment for each of your horses. If equipment must be shared, it should be dipped, washed and dried before use on another horse.

Other biosecurity measures have been delineated by the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service and are listed on page 10.
Biosecurity Measures for Different Situations

The following recommendations from the U.S. Department of Agriculture Plant and Animal Health Inspection Service are based on the belief that you are the best protection your horses have. These guidelines are intended to reduce the chances of an infectious disease being carried onto your farm by people, animals, equipment or vehicles, either accidentally or on purpose.

**Showing Your Horse**

- Use your own trailer whenever possible. Don’t ship your horses with horses from unknown farms.
- Ship only in a trailer or van that has been cleaned and disinfected. If you can “smell horse” in the empty trailer, it has not been cleaned and disinfected properly.
- Don’t let your horse touch unknown horses, especially nose to nose.
- Wash your hands, especially after helping other people with their horses.
- Don’t let strangers pet your horse, especially those with horses at home.
- Before leaving the show grounds, clean and disinfect tack, boots, equipment and grooming supplies. Brush off dirt or manure; then disinfect (spray or wipes are easy to take with you).
- When you get home, shower, blow your nose and put on clean clothes and shoes before going near other horses.

**Visiting Other Farms, Horse Shows or Auctions**

- Have a pair of shoes or boots that you save for visiting and don’t wear around your own horse or wear plastic shoe covers.
- If you are going to be working with horses on another farm, wear coveralls or plan to change clothes before returning home to your horses.
- If there are farms you visit all the time and you can’t change clothes and shoes, be sure their vaccination program and biosecurity practices are as good as your own.

**For Visitors to Your Farm or Horse**

- It is best to have only one public access to your farm. Mark this as the main entrance.
- Park away from the horses. Doing that will help keep disease-carrying organisms from being tracked from car floors or tires to your horses.
- Ask all visitors to wear clean clothes and shoes. Give visitors plastic shoe covers or brush dirt off their shoes and spray them with disinfectant.
- If you have many visitors such as at a farm tour or open house, make a footbath for them to walk through (see inset, page 11).

**Bringing Horses Back from a Show**

- If one or more horses travel to horse shows, all horses on the premises should be vaccinated. Horses that show can bring home infectious agents. Discuss with your veterinarian what vaccinations the horses need and how often.
- If possible, keep horses that were off the farm isolated for at least 2 weeks. At the very least, make sure there is no nose-to-nose contact between horses in the stable.
Bringing in New Horses

This is the most likely way for infectious diseases to come in, especially if horses are coming from other states or from foreign countries.

- Keep every new horse isolated for 30 days. Don’t use pitchforks, grooming tools, or feed and water buckets on any horse but the new one. Mark these with red tape or use red brushes, etc., only for the isolation area.

- Work with the isolated horse last each day. Alternatively, wear boots and coveralls when working with the isolated horse and remove them before working or going near other horses. You can keep these in a plastic-covered tub near the horse. Exercise the isolated horses, alone, at a separate time from others in the stable.

- Always wash your hands and blow your nose after working with the new horse. You could carry germs to your other horses in your nose.

Making an Easy Footbath

You will need:

- A low plastic pan or bin, wide enough to fit an adult’s foot, shallow enough to step into easily

- A plastic doormat (the “fake grass” mats work well)

- A disinfectant that works when manure or dirt is present is best, such as Tek-trol or One Stroke Environ. A 1:10 Clorox solution is also an effective virucidal if the solution is replenished often and kept out of direct sunlight.

- Water

1. Mix the disinfectant with water following label instructions.
2. Put the doormat in the plastic pan.
3. Add disinfectant so that the bottom of the “grass” is wet.
4. Ask visitors to walk through the footbath, wiping their feet on the mat. The “grass” scrubs their shoes a bit as they wipe them, and applies the disinfectant.
5. When the liquid starts to get dirty, empty it and put in new disinfectant.
How to Set Up a Disease Isolation Unit at a Farm or Horse Show

A horse with an infectious disease should be isolated from other horses to prevent the spread of infection. It is also important to prevent exposure by indirect contact from those handling an infected horse and spreading the infection to other horses via touching, equipment and so forth. Isolation can occur by stall confinement if the stall is secure and the horse is not in contact with others that walk by or are housed next to the horse. Often housing at shows is in tight quarters and contact can occur, so extreme care and vigilance in control of these isolation units are required.

If a horse has a fever and neurological signs that would suggest EHV-1 infection, it may be carrying high levels of the virus and become a primary source of spread. The horse should immediately be moved to an isolation area either on or off site.

Any horses that were adjacent to the infected patient that has been moved out should be restricted in their movements and have their temperatures taken twice daily until the nature of the infection is determined. A perimeter and quarantine of that focal area of the barn should be instituted and access to and from the area limited. Horses in that area should be exercised at times when other horses are not in the arena or area. The length of the movement-restriction period will depend on whether other horses develop a fever during the next 7 to 10 days. The end of the quarantine period will be determined by the last horse to develop fever or clinical signs of disease.

An isolation barn that is effective has these characteristics:

- It is well separated from other barns and main horse traffic contact.

- It can be contained. Movement by people in and out can be regulated and controlled.

- Each stall is isolated and prevents direct contact with horses adjacent to each other.

- It has cleanable surfaces, including walls and flooring (mats). Use of liquid laundry detergent is useful in stalls and trailers with large volumes of water. A 10% bleach solution is a good general disinfectant if it is changed and replenished once or twice a day. Other commercial disinfectants can be obtained through your veterinarian.

- It is reserved ONLY for use by infectious disease suspects and is not used by other horses at any time.

- It has water buckets and separate equipment (wheelbarrows, pitchforks, bedding, etc.) used ONLY by the isolation unit.

- It has a sink for handwashing and treatment area. Space must be supplied for storage of things needed for biosecurity such as gloves, disposable coveralls, boots, disinfectant, footbath stations (rubber tubs), and garbage collection and holding for disposables used on the horses. This can be another stall converted into a storage area.

- A person to oversee the isolation stall is designated. This individual should have prior
training in biosecurity. Their responsibility is to ensure that all activities meet with the biosecurity plan outlined for the facility.

- In an ideal situation, an isolation facility would be equipped with an overhead beam or other means for lifting or supporting a down horse, similar to the UC Davis Large Animal Lift (www.vmth.ucdavis.edu/home/VERT/LART/lal.html).

- The designated biosecurity supervisor ensures that people allowed to enter the facility follow appropriate sanitation measures: Rubber boots are dipped in a prescribed foot bath; disposable or dedicated coveralls are used only for one horse stall; disposable gloves are worn; and a treatment coat is worn over the reusable coveralls. If during treatment of the horse facial or other contamination of the caregiver occurs, the caregiver must shower and change clothes before touching other horses.

- Hands are washed for 60 seconds (sing “Happy Birthday” twice at normal tempo) before entering or leaving the isolation area. Use disposable towels and leave in a covered waste container at the site of handwashing.

- A perimeter is set up around the stall area to limit vehicular traffic and entry. This perimeter could be designated with ropes, fencing used for construction sites, and so forth. Random access should be restricted, with only one entry and exit to the area.

- There is appropriate lighting.

### Equipment Needed

- Treatment carts or smocks
- Painter’s disposable coveralls
- Disposable gloves
- Rubber boots
- Foot bath containers
- Garbage bags
- Garbage cans with secure lids
- Disposable plastic shoe covers
- Thermometer for each horse
- Equipment for each horse (drugs in sealed plastic container for that horse, stomach tube, twitch, lip chain, etc.)

One of the isolation units at the UC Davis Veterinary Medical Teaching Hospital.
About Viruses

A virus is a microscopic particle that can infect the cells of animals, yeasts, fungi, plants, and even bacteria. To put the size of a virus into perspective, a medium-sized virion (the form of a virus when it is outside living cells and capable of causing infection) next to a flea is roughly equivalent to a human standing next to a mountain twice the size of Mount Everest. Its size belies its ability to cause widespread devastation and destruction, as it has over many centuries with diseases such as rabies, polio and smallpox.

Viruses have different mechanisms by which they cause disease, depending on the species. Mechanisms at the cellular level primarily include cell lysis—the breaking open and subsequent death of the cell. Although many viruses result in the disruption of a healthy state of equilibrium (homeostasis) and subsequent disease, they may also exist relatively harmlessly within an organism in a latent or dormant state.

The herpes virus—in both humans and animals—is among the most complicated of viruses to understand because of its ability to be dormant in the body and its affinity for nervous tissue. Herpes simplex type 1 in humans, which causes cold sores, can remain dormant within the human body for most of a lifetime. Some researchers have suggested that a specific variant of herpes virus may cause the neurogenerative disease multiple sclerosis in humans.

By contrast, the influenza virus is relatively simple and is transmitted rapidly. It has the ability to mutate and form new strains quickly. Consequently, scientists involved in vaccine development work to stay ahead of the influenza virus by creating new vaccines formulated to combat each year’s version.
Congratulations to Dr. Carrie Finno for being awarded the 2006 John Hughes Memorial Endowment! Dr. Finno’s research will focus on studying cardiovascular and respiratory effects of the sedative xylazine in horses that have fevers. Xylazine is a sedative commonly used in equine practice.

Equine practitioners have observed that intravenous administration of this sedative causes a rapid increase in respiratory rate, shallow respirations, and nostril flare in horses with fevers. With administration of yohimbine, a xylazine antagonist, the tachypnea (increased respiratory rate) will resolve, indicating that the respiratory effects are due to the xylazine. A similar phenomenon has been reported in sheep with a significant decrease in blood oxygen concentrations occurring after xylazine administration.

Dr. Finno’s research will help to increase understanding of the mechanisms behind this reaction and allow veterinary practitioners to prevent this side effect in the future.

Congratulations to Dr. Hugo Hilton for being awarded the 2006 Dan Evans Memorial Endowment! Dr. Hilton will investigate three topical drug preparations to determine the most effective treatment for cannon hyperkeratosis in horses.

Cannon hyperkeratosis is a poorly defined condition that affects the distal hind limbs of horses. Occasionally it affects the forelimbs. The lesions are not painful and are characterized by excessive keratin production (forming a hard growth). No underlying cause for the condition has been identified.

This project will test the hypothesis that local treatment with one of three topical drug preparations will provide better resolution compared with no treatment. The study will also serve as a pilot study for future work in which a larger population of affected horses will be used to investigate the effects of one or more of the trial drugs.
The Equine Medicine Club at UC Davis presents an Equine Medicine Symposium

MAJOR AND MINOR DISASTERS
April 21, 2007
8:00 am - 3:35 pm
1020 Valley Hall
UC Davis School of Veterinary Medicine

This symposium will cover a variety of health-related talks and wetlabs conducted by UC Davis faculty and residents for the general horse owner. Topics include colic, equine lumps and bumps, emergency wound care, barn safety and management, toxic plants, and current hot topics in veterinary medicine.

For more information, visit the Equine Medicine Club’s Web site at www.vetmed.ucdavis.edu/clubs/emc/symp.html. Registration is due by April 2 but late applications will be accepted as space allows.